HRP20180184T1 - Retrovirusni vektori s modificiranim polipurinskim nizom - Google Patents
Retrovirusni vektori s modificiranim polipurinskim nizom Download PDFInfo
- Publication number
- HRP20180184T1 HRP20180184T1 HRP20180184TT HRP20180184T HRP20180184T1 HR P20180184 T1 HRP20180184 T1 HR P20180184T1 HR P20180184T T HRP20180184T T HR P20180184TT HR P20180184 T HRP20180184 T HR P20180184T HR P20180184 T1 HRP20180184 T1 HR P20180184T1
- Authority
- HR
- Croatia
- Prior art keywords
- vector
- integration
- deficient
- retroviral
- sequence
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims 39
- 230000001177 retroviral effect Effects 0.000 title claims 23
- 108090000623 proteins and genes Proteins 0.000 claims 20
- 230000010354 integration Effects 0.000 claims 19
- 230000002950 deficient Effects 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 238000004806 packaging method and process Methods 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 239000002245 particle Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 230000006798 recombination Effects 0.000 claims 6
- 238000005215 recombination Methods 0.000 claims 6
- 238000010361 transduction Methods 0.000 claims 6
- 230000026683 transduction Effects 0.000 claims 6
- 238000001890 transfection Methods 0.000 claims 6
- 102000008579 Transposases Human genes 0.000 claims 4
- 108010020764 Transposases Proteins 0.000 claims 4
- 230000010076 replication Effects 0.000 claims 4
- 230000002463 transducing effect Effects 0.000 claims 4
- 101710163270 Nuclease Proteins 0.000 claims 3
- 102000018120 Recombinases Human genes 0.000 claims 3
- 108010091086 Recombinases Proteins 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 108010077544 Chromatin Proteins 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 210000003483 chromatin Anatomy 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims 2
- 230000003362 replicative effect Effects 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000000311 Cytosine Deaminase Human genes 0.000 claims 1
- 108010080611 Cytosine Deaminase Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 230000007067 DNA methylation Effects 0.000 claims 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 101150042248 Mgmt gene Proteins 0.000 claims 1
- 229930193140 Neomycin Natural products 0.000 claims 1
- 240000007019 Oxalis corniculata Species 0.000 claims 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 claims 1
- 241001492360 Retroviral provirus Species 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- XMQFTWRPUQYINF-UHFFFAOYSA-N bensulfuron-methyl Chemical compound COC(=O)C1=CC=CC=C1CS(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 XMQFTWRPUQYINF-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 108700004025 env Genes Proteins 0.000 claims 1
- 101150030339 env gene Proteins 0.000 claims 1
- 108091006047 fluorescent proteins Proteins 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 229960004927 neomycin Drugs 0.000 claims 1
- 230000001124 posttranscriptional effect Effects 0.000 claims 1
- 229950010131 puromycin Drugs 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Artificial Filaments (AREA)
- Polyurethanes Or Polyureas (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (15)
1. Retrovirusni vektor koji sadrži nukleinsku kiselinu koja sadrži:
a) jednu ili dvije retrovirusne duge terminalne ponavljajuće sekvence (LTR),
b) signal za pakiranje,
c) responsivni element za rev,
d) eukariotski promotor, funkcionalno vezan za
e) heterolognu nukleotidnu sekvencu, gdje izborno heterologna sekvenca sadrži jedan ili više markera gena, opcionalno izabranih između gena za 3-galaktozidazu, higromicinskog gena, blastocidinskog gena, MGMT gena, neomicinskog gena, puromicinskog gena, gena za citozin deaminazu, gena za sekretornu alkalnu fosfatazu, gena za fluorescentni protein, i njihovih kombinacija; terapeutskih gena; antivirusnih gena; antitumorskih gena; gena za citokine; gena koji kodiraju antigene; sekvenci koje se mogu povezati s kromatinom domaćina; sekvenci koje kodiraju protein koji se može povezati s DNK domaćina i kromatinom domaćina i nukleinskom kiselinom vektora; sekvenci koje kodiraju protein koji ima aktivnost metilacije DNK; i njihove kombinacije,
i izborno post-transkripcijski regulatorni element,
naznačen time što retrovirusnom vektoru nedostaje 3’-polipurinski niz (3’-PPT),
izborno funkcionalni cPPT.
2. Retrovirusni vektor prema patentnom zahtjevu 1, koji dalje sadrži:
virusno mjesto početka replikacije, izborno OriP Epstein-Barr virusa ili mjesto početka replikacije SV40 virusa,
sekvencu koja može direktno ili indirektno posredovati u replikaciji nukleinske kiseline vektora od strane domaćina, izborno (a) sekvencu koju prepoznaje replikativni aparat stanice domaćina; (b) sekvencu koja kodira protein koji se može povezati s i/ili da modulira replikativni aparat stanice domaćina; ili (c) sekvencu koja kodira protein koji se može povezati s proteinom iz dijela (b) ili može prepoznati sekvencu vektora,
bakterijsko mjesto početka replikacije i bakterijski selekcijski marker smješten između dvije LTR sekvence.
3. Retrovirusni vektor prema patentnom zahtjevu 1, naznačen time što vektor sadrži:
pojedinačni LTR, i/ili
samoinaktivirajuću deleciju u U3 području LTR, u kojoj je deletirani dio U3 područja izborno zamijenjen inducibilnim promotorom, i/ili
mjesto upravljane rekombinacije, gdje je mjesto upravljane rekombinacije izborno u U3 području LTR i/ili je loxP ili FRT.
4. Retrovirusni vektor prema patentnom zahtjevu 3, naznačen time što vektor sadrži LTR koji sadrži restrikcijsko mjesto u U3 području LTR.
5. Retrovirusni vektor prema patentnom zahtjevu 3 ili 4, naznačen time što vektor sadrži sekvence, izborno LTR sekvence, iz najmanje dva različita retrovirusa, i izborno gdje dodatno najmanje dva različita retrovirusa uključuju lentivirus i/ili najmanje jednu od sekvenci koje kodiraju cis element koji osigurava unakrsno pakiranje vektora u virusnu česticu, gdje je izborno cis element odabran iz grupe koja se sastoji od RRE, fragmenta Env gena iz područja koji omeđuje RRE, i cPPT.
6. Retrovirusna vektorska kazeta za prijenos manjkava u integraciji kojoj nedostaje 3’-polipurinski niz (3’-PPT), naznačena time što retrovirusna vektorska kazeta za prijenos manjkava u integraciji izborno:
nema funkcionalni centralni polipurinski niz (cPPT), i/ili sadrži:
heterologu sekvencu,
pojedinačnu LTR,
samoinaktivirajuću deleciju u U3 području LTR, u kojoj je deletirani dio U3 područja izborno zamijenjen inducibilnim promotorom, i/ili
mjesto upravljane rekombinacije, gdje je mjesto upravljane rekombinacije izborno u U3 području LTR i/ili je loxP i FRT.
7. Rekombinantna retrovirusna čestica koja sadrži vektor prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što je vektor izborno za uporabu u genskoj terapiji, ili retrovirusni provirus proizveden pomoću infekcije ciljanih stanica rekombinantnom retrovirusnom česticom, ili RNA ili mRNA tako proizvedene retrovirusne čestice.
8. Inducibilna stanična linija za pakiranje retrovirusnog vektora koja sadrži retrovirusni vektor prema bilo kojem od prethodnih patentnih zahtjeva i najmanje jedan konstrukt koji kodira jedan ili više proteina potrebnih za pakiranje retrovirusnog vektora.
9. Alat retrovirusnog vektora sadrži:
(a) retrovirusnu vektorsku kazetu za prijenos manjkavu u integraciji kojoj nedostaje 3’-PPT; i
(b) staničnu liniju za pakiranje koja sadrži najmanje jedan konstrukt koji kodira jedan ili više proteina potrebnih za pakiranje retrovirusnog vektora.
10. Postupak za proizvodnju čestica vektora manjkavog u integraciji, koji obuhvaća transfekciju stanične linije za pakiranje retrovirusnom vektorskom kazetom za prijenos manjkavom u integraciji kojoj nedostaje 3’-PPT, gdje stanična linija za pakiranje osigurava proteine za pakiranje retrovirusnog vektora.
11. Retrovirusna čestica manjkava u integraciji prema patentnom zahtjevu 7 za uporabu u postupku za ekspresiju nukleotidne sekvence od interesa u stanici životinje bez integracije nukleotidne sekvence u genom životinje, postupak obuhvaća infekciju jedne ili više stanica retrovirusnom česticom manjkavom u integraciji prema patentnom zahtjevu 7.
12. Vektor manjkav u integraciji prema bilo kojem od prethodnih patentnih zahtjeva za uporabu u postupku za umetanje nukleotidne sekvence od interesa u genom stanice domaćina na mjesto-specifičan način, koji obuhvaća:
(a) transdukciju kompatibilne stanice domaćina vektorom manjkavim u integraciji prema bilo kojem od prethodnih patentnih zahtjeva koji sadrži u funkcionalnoj kombinaciji nukleotidnu sekvencu od interesa i jednu ili više sekvenci za upravljanu rekombinaciju;
i
(b) transfekciju ili transdukciju kompatibilne stanice domaćina nukleinskom kiselinom koja sadrži sekvencu koja kodira nukleazu ili rekombinazu koja može posredovati u mjesto-specifičnoj integraciji u rekombinacijskoj sekvenci, izborno Cre ili Flp, gdje transfekcija ili transdukcija iz dijela (b) može se odvijati odvojeno ili u istom koraku kao dio (a),
(c) gdje je nukleotidna sekvenca od interesa ubačena na mjesto-specifičan način u genom stanice domaćina.
13. Vektor manjkav u integraciji za uporabu u postupku prema patentnom zahtjevu 12, naznačen time što se transfekcija ili transdukcija iz dijela (b) događa u istom koraku kao dio (a) i nukleinska kiselina koja sadrži sekvencu koja kodira nukleazu ili rekombinazu predstavlja vektor manjkav u integraciji iz dijela (a), ili gdje se transfekcija ili transdukcija iz dijela (b) događa u istom koraku kao dio (a) i nukleinska kiselina koja sadrži sekvencu koja kodira nukleazu ili rekombinazu predstavlja zasebni vektor, plazmid, ili molekulu nukleinske kiseline u odnosu na vektor manjkav u integraciji iz dijela (a).
14. Vektor manjkav u integraciji prema bilo kojem od prethodnih patentnih zahtjeva za uporabu u postupku za umetanje nukleotidne sekvence od interesa u genom stanice domaćina na nespecifičan način, koji obuhvaća:
(a) transdukciju stanice domaćina vektorom manjkavim u integraciji prema bilo kojem od patentnih zahtjeva 4 - 6, koji sadrži u funkcionalnoj kombinaciji, nukleotidnu sekvencu od interesa i jednu ili više transpozonskih sekvenci; i
(b) transfekciju ili transdukciju stanice domaćina nukleinskom kiselinom koja sadrži sekvencu koja kodira transpozazu koja može posredovati u integraciji u genom domaćina, gdje se transfekcija ili transdukcija iz dijela (b) može odvijati odvojeno ili u istom koraku kao dio (a),
(c) gdje je nukleotidna sekvenca od interesa ubačena u genom stanice domaćina, i dodatno gdje je transpozon ili transpozaza izborno tipa mariner, dodatno izborno predstavlja „Sleeping Beauty“.
15. Vektor manjkav u integraciji za uporabu u postupku prema patentnom zahtjevu 14, naznačen time što se transfekcija ili transdukcija iz dijela (b) događa u istom koraku kao dio (a) i nukleinska kiselina koja sadrži sekvencu koji kodira transpozazu predstavlja vektor manjkav u integraciji iz dijela (a), ili gdje se transfekcija ili transdukcija iz dijela (b) događa u istom koraku kao dio (a) i nukleinska kiselina koja sadrži sekvencu koja kodira transpozazu predstavlja zasebni vektor, plazmid ili molekulu nukleinske kiseline u odnosu na vektor manjkav u integraciji iz dijela (a).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US711807P | 2007-12-11 | 2007-12-11 | |
PCT/US2008/086409 WO2009076524A2 (en) | 2007-12-11 | 2008-12-11 | Polypurine tract modified retroviral vectors |
EP08859393.4A EP2222861B1 (en) | 2007-12-11 | 2008-12-11 | Polypurine tract modified retroviral vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20180184T1 true HRP20180184T1 (hr) | 2018-04-06 |
Family
ID=40756119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20180184TT HRP20180184T1 (hr) | 2007-12-11 | 2018-01-31 | Retrovirusni vektori s modificiranim polipurinskim nizom |
Country Status (16)
Country | Link |
---|---|
US (2) | US9796987B2 (hr) |
EP (2) | EP2222861B1 (hr) |
JP (2) | JP5749014B2 (hr) |
CY (1) | CY1119905T1 (hr) |
DK (1) | DK2222861T3 (hr) |
ES (1) | ES2664988T3 (hr) |
HR (1) | HRP20180184T1 (hr) |
HU (1) | HUE036103T2 (hr) |
LT (1) | LT2222861T (hr) |
NO (1) | NO2222861T3 (hr) |
PL (1) | PL2222861T3 (hr) |
PT (1) | PT2222861T (hr) |
RS (1) | RS56844B1 (hr) |
SI (1) | SI2222861T1 (hr) |
TR (1) | TR201802323T4 (hr) |
WO (1) | WO2009076524A2 (hr) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006130855A2 (en) | 2005-06-01 | 2006-12-07 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
EP2526774A3 (en) | 2006-07-21 | 2013-03-06 | California Institute of Technology | Targeted gene delivery for dendritic cell vaccination |
RS56844B1 (sr) | 2007-12-11 | 2018-04-30 | Univ North Carolina Chapel Hill | Retrovirusni vektori sa modifikovanim polipurinskim nizom |
SI2770061T1 (sl) * | 2009-07-24 | 2019-02-28 | Immune Design Corp. | Neintegrirani lentiviralni vektorji |
JP2014510721A (ja) | 2011-02-15 | 2014-05-01 | イミューン デザイン コーポレイション | ベクターワクチンによる免疫原特異的免疫応答を強化するための方法 |
JP6054942B2 (ja) | 2011-04-08 | 2016-12-27 | イミューン デザイン コーポレイション | 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法 |
US8323662B1 (en) | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
DK2831095T3 (en) | 2012-03-30 | 2019-02-18 | Immune Design Corp | LENTIVIRAL VECTOR PARTICLES WITH IMPROVED TRANSDUCTION EFFICIENCY FOR CELL EXPRESSING DC SIGN |
KR102136433B1 (ko) | 2012-05-16 | 2020-07-22 | 이뮨 디자인 코포레이션 | Hsv-2 백신 |
EP3542816A1 (en) | 2014-02-14 | 2019-09-25 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
CA2955015A1 (en) | 2014-07-15 | 2016-01-21 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
KR101607282B1 (ko) | 2014-12-18 | 2016-03-29 | 충남대학교산학협력단 | 유리형 산화환원조절단백-1 및 이를 함유하는 항염증 약학조성물 |
US10350245B2 (en) | 2015-01-21 | 2019-07-16 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
WO2017066570A1 (en) * | 2015-10-15 | 2017-04-20 | The University Of North Carolina At Chapel Hill | Methods and compositions for integration-defective lentiviral vectors |
WO2017068419A2 (en) | 2015-10-22 | 2017-04-27 | Juno Therapeutics Gmbh | Methods, kits, agents and apparatuses for transduction |
AU2016354102B2 (en) | 2015-11-09 | 2022-05-12 | Immune Design Corp. | A retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids |
MX2018005467A (es) | 2015-11-09 | 2018-12-11 | Immune Design Corp | Composiciones que comprenden vectores lentivirales que expresan interleucina-12, y metodos de uso de las mismas. |
JP2019509275A (ja) | 2016-02-23 | 2019-04-04 | イミューン デザイン コーポレイション | マルチゲノムレトロウイルスベクター調製物ならびにそれらを産生および使用するための方法およびシステム |
BR112018070934A2 (pt) | 2016-04-15 | 2019-02-26 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras variantes ligantes de icos e usos das mesmas |
IL310729A (en) | 2016-04-15 | 2024-04-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins that are variants of CD80 and their uses |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
CN110088127A (zh) | 2016-07-28 | 2019-08-02 | 高山免疫科学股份有限公司 | Cd155变体免疫调节蛋白及其用途 |
CN109804089A (zh) | 2016-07-29 | 2019-05-24 | 朱诺治疗学股份有限公司 | 用于评估复制型病毒存在或不存在的方法 |
MA46998A (fr) | 2016-12-05 | 2019-10-09 | Juno Therapeutics Inc | Production de cellules modifiées pour une thérapie cellulaire adoptive |
AU2018235838B2 (en) | 2017-03-16 | 2023-12-14 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
AU2018235835A1 (en) | 2017-03-16 | 2019-09-05 | Alpine Immune Sciences, Inc. | PD-L2 variant immunomodulatory proteins and uses thereof |
CN110831963A (zh) | 2017-03-16 | 2020-02-21 | 高山免疫科学股份有限公司 | Pd-l1变体免疫调节蛋白及其用途 |
CA3070573A1 (en) | 2017-07-29 | 2019-02-07 | Juno Therapeutics, Inc. | Reagents for expanding cells expressing recombinant receptors |
BR112020001605A2 (pt) | 2017-08-09 | 2020-08-11 | Juno Therapeutics Inc | métodos para produzir composições de células geneticamente modificadas e composições relacionadas |
CA3077509A1 (en) | 2017-10-10 | 2019-04-18 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
JP7282760B2 (ja) | 2017-10-18 | 2023-05-29 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントicosリガンド免疫調節タンパク質ならびに関連する組成物および方法 |
EP3704230A1 (en) | 2017-11-01 | 2020-09-09 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
CA3080509A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for producing a t cell composition |
CN112041430A (zh) | 2017-12-08 | 2020-12-04 | 朱诺治疗学股份有限公司 | 用于培养细胞的无血清培养基配制品及其使用方法 |
BR112020013236A2 (pt) | 2018-01-03 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso |
EP3746569A1 (en) | 2018-01-31 | 2020-12-09 | Juno Therapeutics, Inc. | Methods and reagents for assessing the presence or absence of replication competent virus |
WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
AU2019345151A1 (en) | 2018-09-19 | 2021-04-29 | Alpine Immune Sciences, Inc. | Methods and uses of variant CD80 fusion proteins and related constructs |
BR112021008289A2 (pt) | 2018-11-01 | 2021-10-26 | Juno Therapeutics, Inc. | Métodos para tratamento utilizando receptores de antígeno quimérico específico para antígeno de maturação de célula b |
CN113271963A (zh) | 2018-11-16 | 2021-08-17 | 朱诺治疗学股份有限公司 | 给予工程化t细胞以治疗b细胞恶性肿瘤的方法 |
WO2020113188A2 (en) | 2018-11-30 | 2020-06-04 | Juno Therapeutics, Inc. | Methods for dosing and treatment of b cell malignancies in adoptive cell therapy |
EP3887394A2 (en) | 2018-11-30 | 2021-10-06 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
SG11202105502RA (en) | 2018-11-30 | 2021-06-29 | Juno Therapeutics Inc | Methods for treatment using adoptive cell therapy |
KR20220035032A (ko) | 2019-04-17 | 2022-03-21 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 변이체 icos 리간드(icosl) 융합 단백질의 방법 및 용도 |
US20220228101A1 (en) | 2019-06-07 | 2022-07-21 | Juno Therapeutics, Inc. | Automated t cell culture |
WO2020252218A1 (en) | 2019-06-12 | 2020-12-17 | Juno Therapeutics, Inc. | Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein |
WO2021035194A1 (en) | 2019-08-22 | 2021-02-25 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
US20220412954A1 (en) | 2019-11-05 | 2022-12-29 | Juno Therapeutics, Inc. | Methods of determining attributes of therapeutic t cell compositions |
MX2022006715A (es) | 2019-12-06 | 2022-09-23 | Juno Therapeutics Inc | Metodos relacionados con toxicidad y respuesta asociada con terapia celular para tratar neoplasias malignas de celulas b. |
BR112022014501A2 (pt) | 2020-01-24 | 2022-09-20 | Juno Therapeutics Inc | Métodos para dosagem e tratamento de linfoma folicular e linfoma de zona marginal em terapia celular adotiva |
EP4097218A1 (en) | 2020-01-28 | 2022-12-07 | Juno Therapeutics, Inc. | Methods for t cell transduction |
US20230149462A1 (en) | 2020-04-10 | 2023-05-18 | Juno Therapeutics, Inc. | Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen |
CN115812077A (zh) | 2020-05-08 | 2023-03-17 | 高山免疫科学股份有限公司 | April和baff抑制性免疫调节蛋白及其使用方法 |
US20230178239A1 (en) | 2020-05-13 | 2023-06-08 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
WO2022133030A1 (en) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Combination therapy of a cell therapy and a bcl2 inhibitor |
CN117321200A (zh) | 2021-03-22 | 2023-12-29 | 朱诺治疗学股份有限公司 | 评估病毒载体颗粒效力的方法 |
KR20230159851A (ko) | 2021-03-22 | 2023-11-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 치료 세포 조성물의 효력을 결정하는 방법 |
BR112023019847A2 (pt) | 2021-03-29 | 2023-11-07 | Juno Therapeutics Inc | Métodos para dosagem e tratamento com uma combinação de uma terapia com inibidor de ponto de verificação e uma terapia com célula t car |
CA3216795A1 (en) | 2021-05-07 | 2022-11-10 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
WO2023172883A1 (en) | 2022-03-07 | 2023-09-14 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses |
WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
WO2024077018A2 (en) | 2022-10-04 | 2024-04-11 | Alpine Immune Sciences, Inc. | Methods and uses of taci-fc fusion immunomodulatory protein |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861161A (en) | 1994-09-07 | 1999-01-19 | Universite De Montreal | Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions |
DE69626681T2 (de) * | 1995-11-28 | 2004-02-12 | The Johns Hopkins University School Of Medicine | Konditionell-replizierende virale vektoren und ihre verwendung. |
WO2001030965A2 (en) | 1999-10-28 | 2001-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of in vivo gene transfer using a sleeping beauty transposon system |
US6673567B2 (en) | 2000-03-23 | 2004-01-06 | E. I. Du Pont De Nemours And Company | Method of determination of gene function |
WO2002042482A2 (en) * | 2000-11-27 | 2002-05-30 | Chiron Corporation | Functional lentiviral vector from an mlv-based backbone |
AU2003260769A1 (en) * | 2002-09-03 | 2004-03-29 | Oxford Biomedica (Uk) Limited | Retroviral vector and stable packaging cell lines |
US7220578B2 (en) * | 2002-11-27 | 2007-05-22 | Tal Kafri | Single LTR lentivirus vector |
WO2005023313A1 (en) * | 2003-09-09 | 2005-03-17 | Virxsys Corporation | Lentivirus vector-based approaches for generating an immune response to hiv humans |
GB0325379D0 (en) | 2003-10-30 | 2003-12-03 | Oxford Biomedica Ltd | Vectors |
US20060019393A1 (en) * | 2003-12-04 | 2006-01-26 | Cannon Paula M | Minimal lentiviral vector system |
JP2007054069A (ja) * | 2005-08-24 | 2007-03-08 | Medizinische Hochschule Hannover | 自己不活性化レトロウイルスベクター |
EP1757703A3 (en) | 2005-08-24 | 2007-12-05 | Medizinische Hochschule Hannover | Self-inactivating retroviral vector |
RS56844B1 (sr) | 2007-12-11 | 2018-04-30 | Univ North Carolina Chapel Hill | Retrovirusni vektori sa modifikovanim polipurinskim nizom |
-
2008
- 2008-12-11 RS RS20180107A patent/RS56844B1/sr unknown
- 2008-12-11 EP EP08859393.4A patent/EP2222861B1/en active Active
- 2008-12-11 PL PL08859393T patent/PL2222861T3/pl unknown
- 2008-12-11 EP EP17204678.1A patent/EP3342872A1/en not_active Withdrawn
- 2008-12-11 NO NO08859393A patent/NO2222861T3/no unknown
- 2008-12-11 SI SI200831929T patent/SI2222861T1/en unknown
- 2008-12-11 PT PT88593934T patent/PT2222861T/pt unknown
- 2008-12-11 ES ES08859393.4T patent/ES2664988T3/es active Active
- 2008-12-11 DK DK08859393.4T patent/DK2222861T3/en active
- 2008-12-11 TR TR2018/02323T patent/TR201802323T4/tr unknown
- 2008-12-11 HU HUE08859393A patent/HUE036103T2/hu unknown
- 2008-12-11 LT LTEP08859393.4T patent/LT2222861T/lt unknown
- 2008-12-11 US US12/747,076 patent/US9796987B2/en active Active
- 2008-12-11 JP JP2010538155A patent/JP5749014B2/ja active Active
- 2008-12-11 WO PCT/US2008/086409 patent/WO2009076524A2/en active Application Filing
-
2015
- 2015-01-28 JP JP2015013974A patent/JP6001702B2/ja active Active
-
2017
- 2017-10-23 US US15/790,530 patent/US10017785B2/en active Active
-
2018
- 2018-01-31 HR HRP20180184TT patent/HRP20180184T1/hr unknown
- 2018-02-09 CY CY20181100167T patent/CY1119905T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP2222861A4 (en) | 2011-12-28 |
TR201802323T4 (tr) | 2018-03-21 |
WO2009076524A2 (en) | 2009-06-18 |
HUE036103T2 (hu) | 2018-06-28 |
PT2222861T (pt) | 2018-02-16 |
US20100323403A1 (en) | 2010-12-23 |
JP2015119715A (ja) | 2015-07-02 |
EP2222861A2 (en) | 2010-09-01 |
PL2222861T3 (pl) | 2018-04-30 |
US10017785B2 (en) | 2018-07-10 |
ES2664988T3 (es) | 2018-04-24 |
EP3342872A1 (en) | 2018-07-04 |
WO2009076524A3 (en) | 2009-09-11 |
JP2011505835A (ja) | 2011-03-03 |
LT2222861T (lt) | 2018-03-26 |
JP5749014B2 (ja) | 2015-07-15 |
RS56844B1 (sr) | 2018-04-30 |
CY1119905T1 (el) | 2018-06-27 |
SI2222861T1 (en) | 2018-04-30 |
NO2222861T3 (hr) | 2018-05-05 |
DK2222861T3 (en) | 2018-02-05 |
US9796987B2 (en) | 2017-10-24 |
EP2222861B1 (en) | 2017-12-06 |
US20180119170A1 (en) | 2018-05-03 |
JP6001702B2 (ja) | 2016-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20180184T1 (hr) | Retrovirusni vektori s modificiranim polipurinskim nizom | |
JP2011505835A5 (hr) | ||
US11827881B2 (en) | Systems, methods, and compositions for site-specific genetic engineering using programmable addition via site-specific targeting elements (paste) | |
US8865467B2 (en) | Single lentiviral vector system for induced pluripotent (iPS) stem cells derivation | |
US20170145438A1 (en) | Viral Vectors for Gene Editing | |
JP2012080889A (ja) | 多コンパートメント真核生物発現系 | |
US20210047643A1 (en) | Gene editing using homology-independent universal genome engineering technology | |
WO2017212264A1 (en) | Method of integrating donor dna into target dna | |
US9085767B2 (en) | Enhancer-containing gene trap vectors for random and targeted gene trapping | |
Santhosh et al. | A lentiviral vector with novel multiple cloning sites: stable transgene expression in vitro and in vivo | |
US20220168342A1 (en) | Genome edited primary b cell and methods of making and using | |
CN104093834A (zh) | 表达盒 | |
AU2017225350A1 (en) | Promoter | |
JP4766297B2 (ja) | 非ウィルス由来のエンハンサーと、cPPTと、CTSとを含むことを特徴とするベクター | |
Chang et al. | A replication-competent feline leukemia virus, subgroup A (FeLV-A), tagged with green fluorescent protein reporter exhibits in vitro biological properties similar to those of the parental FeLV-A | |
Fan et al. | Impact of the size of CRISPR-Cas gene cassettes on the packaging efficiency and transduction titer of lentiviral vectors | |
WO2024095188A2 (en) | A screening method | |
WO2023057880A1 (en) | Crispr/cas9-based fusion proteins for modulating gene expression and methods of use | |
Chaudhury et al. | Use of the pBUTR Reporter System for Scalable Analysis of 3′ UTR-Mediated Gene Regulation | |
Torres-Ruiz Raul et al. | Efficient Recreation of t (11; 22) EWSR1-FLI1+ in Human Stem Cells Using CRISPR/Cas9 | |
CN117355607A (zh) | 非病毒同源性介导的末端连接 | |
Blø et al. | Expanding the spectrum of genetic elements transferable by retroviral vectors |